表紙:多形性膠芽腫(2030年まで):世界の医薬品予測と市場分析
市場調査レポート
商品コード
1054036

多形性膠芽腫(2030年まで):世界の医薬品予測と市場分析

Glioblastoma Multiforme - Global Drug Forecast and Market Analysis to 2030

出版日: | 発行: GlobalData | ページ情報: 英文 127 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
多形性膠芽腫(2030年まで):世界の医薬品予測と市場分析
出版日: 2021年12月22日
発行: GlobalData
ページ情報: 英文 127 Pages
納期: 即納可能 即納可能とは
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の多形性膠芽腫(GBM)市場は、主にテモゾロミドとベバシズマブに依存しており、2020年の総売上5億4,910万ドルのうち、それぞれ46%と51%を占めています。この市場が真の成長を遂げるためには、テモゾロミドのジェネリック医薬品の存在とベバシズマブのバイオシミラーの導入により、現在販売されている製品がほぼすべて新しいパイプライン製品に置き換わる必要があります。しかし、後期段階のGBM試験については、歴史的に高い失敗率が観察されており、パイプライン予測に影響を与え、市場成長の妨げとなる可能性があります。それでも、8つのパイプライン薬剤が8MMに参入し、2030年までに4.7%のCAGRでGBMの成長を8億6,850万米ドルに押し上げると予想されます。

当レポートでは多形性膠芽腫(GBM)の世界市場を調査し、市場の概要、病気の概要、アンメットニーズと機会、研究開発戦略、パイプライン評価と分析、競合情勢など、体系的な情報を提供しています。

目次

目次

第1章 多形性膠芽腫:エグゼクティブサマリー

  • 市場は、2030年までに8MMで8億6,850万米ドルに達すると予測される
  • Merck & Co.が初期段階のポートフォリオを拡大し、Roche が侵食される一方で、GBM-AGILE Candidatesが市場に浸透
  • 特にMGMTプロモーターのメチル化されていない患者と切除不能な患者における、高いアンメットニーズの存在
  • より良い予後マーカーと創薬ターゲットを備えた新規参入者の機会
  • 予測期間中に発売が見込まれる新規GBM-AGILE薬剤候補および免疫療法
  • 医師の考え

第2章 イントロダクション

  • 触媒
  • 関連レポート
  • 今後のレポート

第3章 病気の概要

  • 病因と病態生理学
    • 病因
    • 病態生理学
  • 分類またはステージングシステム

第4章 疫学

  • 病気の背景
  • 危険因子と併存疾患
  • 世界的および歴史的動向
  • 8MM予測調査手法
    • ソース
    • 予測の前提条件と方法
    • 脳腫瘍の診断されたインシデントケース
    • タイプ別、脳腫瘍の診断されたインシデントケース
    • グレード別、膠芽腫の診断されたインシデントケース
    • 起源別、膠芽腫の診断されたインシデントケース
    • バイオマーカー別、膠芽腫の診断されたインシデントケース
    • 突然変異別、膠芽腫の診断されたインシデントケース
    • 脳腫瘍の5年間の診断された一般的症例
  • 議論
    • 疫学予測洞察
    • COVID-19の影響
  • 脳腫瘍の疫学予測(2020年~2030年)
    • 脳腫瘍の診断されたインシデントケース
    • 脳腫瘍の年齢別、診断されたインシデントケース
    • 脳腫瘍の性別、診断されたインシデントケース
    • タイプ別、脳腫瘍の診断されたインシデントケース
    • グレード別、膠芽腫の診断されたインシデントケース
    • 起源別、膠芽腫の診断されたインシデントケース
    • バイオマーカー別、膠芽腫の診断されたインシデントケース
    • 突然変異別、膠芽腫の診断されたインシデントケース
    • 脳腫瘍の5年間の診断された一般的症例
    • 分析の限界
    • 分析の強み

第5章 疾病管理

  • 診断と治療の概要
  • 疾病管理に関するKOLインサイト

第6章 現在の治療オプション

  • 概要

第7章 アンメットニーズと機会の評価

  • 概要
  • バイオマーカーと創薬ターゲットの特定と検証
  • 血液脳関門を克服して治療の有効性を改善
  • MGMTのメチル化されていない切除不能な患者のためのより良い治療選択肢
  • 疑似進行と真の進行の区別

第9章 研究開発戦略

  • 概要
    • GBMにおける免疫療法の有効性
    • 予測バイオマーカーと標的療法
    • 治療管理ルートの改善
  • 臨床試験デザイン
    • 臨床評価項目
    • その他の傘またはプラットフォームの試験デザイン
    • コンパレータアーム

第10章 パイプライン評価

  • 概要
  • 臨床開発における有望な薬剤

第11章 パイプライン評価分析

  • 概要
  • 競争力のある評価

第12章 現在および将来の企業

  • 概要
  • 取引動向

第13章 市場の見通し

第14章 付録

図表

List of Tables

List of Tables

  • Table 1: Glioblastoma Multiforme: Key Metrics in the 8MM
  • Table 2: Classification of Key Gliomas and Corresponding Diagnostic Genes
  • Table 3: Risk Factors and Comorbid Conditions Associated with Brain Cancer
  • Table 4: Treatment Guidelines for GBM
  • Table 5: Top 10 Deals by Value, 2019-2021
  • Table 6: GBM Market - Global Drivers and Barriers, 2020-2030
  • Table 7: Key Events Impacting Sales for GBM in the US, 2020-2030
  • Table 8: GBM Market - Drivers and Barriers in the US, 2020-2030
  • Table 9: Key Events Impacting Sales for GBM in the 5EU, 2020-2030
  • Table 10: GBM Market - Drivers and Barriers in the 5EU, 2020-2030
  • Table 11: Key Events Impacting Sales for GBM in Japan, 2020-2030
  • Table 12: GBM Market - Drivers and Barriers in Japan, 2020-2030
  • Table 13: Key Events Impacting Sales for GBM in China, 2020-2030
  • Table 14: GBM Market - Drivers and Barriers in China, 2020-2030
  • Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global (8MM) Sales Forecast by Country for GBM in 2020 and 2030
  • Figure 2: Analysis of the Company Portfolio Gap in GBM During the Forecast Period, 2020-2030
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Recurrent GBM During the Forecast Period
  • Figure 4: Genetic and Molecular Pathogenesis of GBM
  • Figure 5: 8MM, Diagnosed Incidence of Brain Cancer, Men, Cases Per 100,000 Population All Ages, 2010-2030
  • Figure 6: 8MM, Diagnosed Incidence of Brain Cancer, Women, Cases Per 100,000 Population All Ages, 2010-2030
  • Figure 7: 8MM, Sources Used to Forecast Diagnosed Incident Cases Brain Cancer (ICD-10 = C70, C71, C72)
  • Figure 8: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of Brain Cancer (ICD-10 = C70, C71, C72)
  • Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Brain Cancer (ICD-10 = C70, C71, C72) by Type
  • Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Glioblastoma by Grade (WHO Grading System)
  • Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Glioblastoma by Origin
  • Figure 12: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Glioblastoma by Biomarkers and Mutations
  • Figure 13: 8MM, Diagnosed Incident Cases of Brain Cancer, N, Both Sexes, All Ages, 2020
  • Figure 14: 8MM, Diagnosed Incident Cases of Brain Cancer by Age, N, Both Sexes, 2020
  • Figure 15: 8MM, Diagnosed Incident Cases of Brain Cancer by Sex, N, All Ages, 2020
  • Figure 16: 8MM, Diagnosed Prevalent Cases of Brain Cancer by Type, N, Both Sexes, All Ages, 2020
  • Figure 17: 8MM, Diagnosed Incident Cases of Glioblastoma by Grade, N, Both Sexes, All Ages, 2020
  • Figure 18: 8MM, Diagnosed Incident Cases of Glioblastoma by Origin, N, Both Sexes, All Ages, 2020
  • Figure 19: 8MM, Diagnosed Prevalent Cases of Glioblastoma by Biomarkers, N, Both Sexes, All Ages, 2020
  • Figure 20: 8MM, Diagnosed Prevalent Cases of Glioblastoma by Mutations, N, Both Sexes, All Ages, 2020
  • Figure 21: 8MM, Five-Year Diagnosed Prevalent Cases of Brain Cancer, N, Both Sexes, All Ages, 2020
  • Figure 22: Overview of the Treatment Algorithm in GBM
  • Figure 23: Unmet Needs and Opportunities in GBM
  • Figure 24: Overview of the Development Pipeline in GBM
  • Figure 25: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for GBM in the 8MM During the Forecast Period
  • Figure 26: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Temodar, in Newly Diagnosed GBM
  • Figure 27: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Gleostine, in Recurrent GBM
  • Figure 28: Analysis of the Company Portfolio Gap in GBM During the Forecast Period
  • Figure 29: Global (8MM) Sales Forecast by Country for GBM in 2020 and 2030
  • Figure 30: Sales Forecast by Class for GBM in the US in 2020 and 2030
  • Figure 31: Sales Forecast by Class for GBM in the 5EU in 2020 and 2030
  • Figure 32: Sales Forecast by Class for GBM in Japan in 2020 and 2030
  • Figure 33: Sales Forecast by Class for GBM in China in 2020 and 2030
目次
Product Code: GDHC237PIDR

Glioblastoma multiforme (GBM) is now defined by the WHO 2021 as a diffuse astrocytic glioma with no mutations in IDH genes or histone H3 genes. It is the most common primary brain tumor in humans. Like other astrocytomas, GBM originates from astrocytes, a type of glial cells that are non-neuronal and function to provide structural and biochemical support to the brain's neuronal network. GBM continues to be a disease with some of the highest unmet needs in oncology, with patients having a median overall survival (OS) of between one and two years. The lack of therapies is primarily due to the inability of drugs to penetrate the blood-brain barrier (BBB).

The market of GBM relies predominantly on temozolomide and bevacizumab, which accounted for 46% and 51%, respectively, of the total $549.1M sales in 2020. For this market to witness true growth, the currently marketed products would need to be almost entirely replaced by new pipeline products, owing to the significant presence of generic temozolomide and the introduction of bevacizumab biosimilars. However, a high failure rate has been historically observed for late-stage GBM trials and may impact the pipeline forecast and impede the market growth. Nevertheless, eight pipeline agents are expected to enter the 8MM and drive the GBM growth to $868.5M by 2030 at a Compound Annual Growth Rate (CAGR) of 4.7%.

Key Highlights

  • The main drivers of growth include the anticipated approval and launch of eight pipeline agents during the forecast period, of which cancer vaccines and protein kinase inhibitors are the dominating classes.
  • The primary barrier to growth in the forecast period will be the high failure rates historically observed for Phase III GBM trials, impacting the pipeline forecast. The high genericization of temozolomide and recent patent expiration of Avastin, leading to biosimilar entry, also reduces the Glioblastoma Multiforme (GBM) market potential.
  • DCVax-L, regorafenib, and paxalisib are the three pipeline agents expected to generate the highest sales for GBM from 2020-2030.
  • Aside from improving OS, other key unmet needs in the GBM market include; Predictive biomarkers to guide personalized therapy and the need to find more efficacious treatment in O6-methylguanine-DNA methyltransferase (MGMT) unmethylated patients who typically have a poor response to temozolomide.

KEY QUESTIONS ANSWERED

  • Eight Phase II-III pipeline agents are expected to enter the Glioblastoma market from 2024 onwards. What impact will these agents have on the market?
  • Which of these drugs will have the highest peak sales, and why?
  • What are the current unmet needs in GBM, which pipeline agents are positioned to counter these unmet needs?
  • What are the opportunities for R&D?
  • What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?
  • What is the expected future uptake of protein kinase inhibitors across the 8MM?

Scope

  • Overview of Glioblastoma Multiforme including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline Glioblastoma Multiforme market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting Glioblastoma Multiforme therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II - III).
  • Analysis of the current and future market competition in the global Glioblastoma Multiforme therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global Glioblastoma Multiforme therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Glioblastoma Multiforme market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global Glioblastoma Multiforme therapeutics market from 2020-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1 Glioblastoma Multiforme: Executive Summary

  • 1.1 The Glioblastoma Multiforme Market is Forecast to Reach $868.5M by 2030 Across the 8MM
  • 1.2 GBM-AGILE Candidates Set to Penetrate the Market While Merck & Co. Expands its Early-Stage Portfolio and Roche Experiences Erosion
  • 1.3 High Unmet Needs Exist in the GBM Market, Especially in MGMT-Promoter Unmethylated Patients and Unresectable Patients
  • 1.4 Opportunities for New Entrants with Better Markers of Prognosis and Drug Targets
  • 1.5 Novel GBM-AGILE Drug Candidates and Immunotherapies Expected to Launch During the Forecast Period
  • 1.6 What Do Physicians Think?

2 Introduction

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Disease Overview

  • 3.1 Etiology and Pathophysiology
    • 3.1.1 Etiology
    • 3.1.2 Pathophysiology
  • 3.2 Classification or Staging Systems

4 Epidemiology

  • 4.1 Disease Background
  • 4.2 Risk Factors and Comorbidities
  • 4.3 Global and Historical Trends
  • 4.4 8MM Forecast Methodology
    • 4.4.1 Sources
    • 4.4.2 Forecast Assumptions and Methods
    • 4.4.3 Diagnosed Incident Cases of Brain Cancer
    • 4.4.4 Diagnosed Incident Cases of Brain Cancer by Type
    • 4.4.5 Diagnosed Incident Cases of Glioblastoma by Grade
    • 4.4.6 Diagnosed Incident Cases of Glioblastoma by Origin
    • 4.4.7 Diagnosed Incident Cases of Glioblastoma by Biomarkers
    • 4.4.8 Diagnosed Incident Cases of Glioblastoma by Mutations
    • 4.4.9 Five-Year Diagnosed Prevalent Cases of Brain Cancer
  • 4.5 Discussion
    • 4.5.1 Epidemiological Forecast Insight
    • 4.5.2 COVID-19 Impact
  • 4.6 Epidemiological Forecast for Brain Cancer (2020-2030)
    • 4.6.1 Diagnosed Incident Cases of Brain Cancer
    • 4.6.2 Age-Specific Diagnosed Incident Cases of Brain Cancer
    • 4.6.3 Sex-Specific Diagnosed Incident Cases of Brain Cancer
    • 4.6.4 Diagnosed Incident Cases of Brain Cancer by Type
    • 4.6.5 Diagnosed Incident Cases of Glioblastoma by Grade
    • 4.6.6 Diagnosed Incident Cases of Glioblastoma by Origin
    • 4.6.7 Diagnosed Incident Cases of Glioblastoma by Biomarkers
    • 4.6.8 Diagnosed Incident Cases of Glioblastoma by Mutations
    • 4.6.9 Five-Year Diagnosed Prevalent Cases of Brain Cancer
    • 4.6.10 Limitations of the Analysis
    • 4.6.11 Strengths of the Analysis

5 Disease Management

  • 5.1 Diagnosis and Treatment Overview
  • 5.2 KOL Insights on Disease Management

6 Current Treatment Options

  • 6.1 Overview

7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Identification and Validation of Biomarkers and Drug Targets
  • 7.3 Overcoming the Blood-Brain Barrier to Improve the Efficacy of Treatments
  • 7.4 Better Treatment Options for MGMT Unmethylated and Unresectable Patients
  • 7.5 Differentiating Pseudoprogression and True Progression

9 R&D Strategies

  • 9.1 Overview
    • 9.1.1 The Efficacy of Immunotherapy in GBM
    • 9.1.2 Predictive Biomarkers and Targeted Therapy
    • 9.1.3 Improving Therapy Administration Routes
  • 9.2 Clinical Trials Design
    • 9.2.1 Clinical Endpoints
    • 9.2.2 More Umbrella or Platform Trial Designs
    • 9.2.3 Comparator Arms

10 Pipeline Assessment

  • 10.1 Overview
  • 10.2 Promising Drugs in Clinical Development

11 Pipeline Valuation Analysis

  • 11.1 Overview
  • 11.2 Competitive Assessment

12 Current and Future Players

  • 12.1 Overview
  • 12.2 Deal-Making Trends

13 Market Outlook

14 Appendix